Service
Corporate
Service
27/04/2022
[Congress] Meet Oncodesign in person this spring
Check out where to meet Oncodesign this spring... surely we can arrange a meeting somewhere.
Service
05/04/2022
[EN] How to Better Optimize an Oncology Drug Discovery Program
Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...
Service
28/03/2022
Scientific Posters | AACR 2022
Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)
![[CONGRESS] Microbiome & Probiotics](https://www.oncodesign.com/wp-content/uploads/2022/03/Congres-Microbiome-March-2022.jpg)
Service
18/03/2022
[Congress] AACR Annual Meeting | 8-13 April 2022
Meet us in person at the Annual Meeting of the AACR in New Orleans!
Service
16/03/2022
[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Service
14/03/2022
[CONGRESS] Microbiome & Probiotics, 29-30 March 2022
Meet us at the Microbiome & Probiotics congress in San Diego | March 2022. Explore our expertise in assessing the role of microbiome in drug discovery
Service
24/02/2022
Abzena, Alira Health et Oncodesign lancent DRIVE-Biologics, une nouvelle offre de services premium
A lire le CP sur l'offre conjointe Abzena x Alira Heath x Oncodesign : une nouvelle solution intégrée unique depuis la découverte de biologiques jusqu'à leur fabrication clinique et leur commercialisation.
Service
22/02/2022
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance [EN]
A lire dans Communication Biologics (Nature), les données du programme préclinique exoSTING, auquel Oncodesign a participé (Hepa1-6).
Service
18/02/2022
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity [EN)
A lire dans Science Advances : le programme de développement préclinique d'exoASO-STAT6, un nouveau candidat de médecine de précision à base d'exosomes pour le traitement des tumeurs riches en macrophages.
Service
14/01/2022
[Congress] Microbiome Movement Drug Development
Oncodesign will be at the digital event Microbiome Movement Drug Development. Take the opportunity to learn more about SOLO Microbiome.
Service
11/12/2021
Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections
SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.
Service
07/12/2021
[EN] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases
Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.